New HCPCS Code for CYRAMZA®

• Amanda Bridges
• December 4, 2015
• Drugs, News

Announcing the assignment of a product-specific Healthcare Common Procedure Coding System (HCPCS) code for CYRAMZA^® (ramucirumab) for injection.         

The new code, J9308, is defined as Injection, ramucirumab, 5 mg. This code is effective January 1, 2016.

*NDC has been “zero-filled” to ensure creation of an 11-digit code that meets HIPAA standards. The zero-fill location is indicated in bold. HIPAA=Health Insurance Portability and Accountability Act.

[su_note note_color=”#ff6666″ text_color=”#000″]

WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND HEALING

Hemorrhage: CYRAMZA increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue CYRAMZA in patients who experience severe bleeding.

Gastrointestinal Perforation: CYRAMZA can increase the risk of gastrointestinal perforation, a potentially fatal event. Permanently discontinue CYRAMZA in patients who experience a gastrointestinal perforation.

Impaired Wound Healing: Impaired wound healing can occur with antibodies inhibiting the VEGF pathway. Discontinue CYRAMZA therapy in patients with impaired wound healing. Withhold CYRAMZA prior to surgery and discontinue CYRAMZA if a patient develops wound healing complications.[/su_note]

CYRAMZA is a human vascular endothelial growth factor receptor 2 antagonist indicated: 

• As a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastroesophageal (GE) junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy
• In combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA
• In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil), for the treatment of metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine

For more information, please visit www.CYRAMZAhcp.com. For full Prescribing Information, please click here.